TABLE 1:
Clinical characteristics and therapeutic regimens
| Patient No./Age (y)/Sex | Brain Tumor | Surgery | Radiotherapy (dose/Fx) | Chemotherapy |
|---|---|---|---|---|
| 1/70/M | Malignant lymphoma | Biopsy | 40 Gy WB with 14 Gy boost/22 Fx | MTX |
| 2/53/F | Malignant lymphoma | None | 40 Gy WB with 14 Gy boost/28 Fx | MTX, ICE |
| 3/55/F | Metastatic tumor (pulmonary adenocarcinoma) | Total removal | 30 Gy WB/10 Fx | None |
| 4/53/M | Glioblastoma | Partial removal | 30 Gy WB/15 Fx | CE, other |
| 5/64/M | Metastatic tumor (pulmonary adenocarcinoma) | Total removal | 30 Gy WB with 15 Gy boost (stereotactic radiosurgery)/11 Fx | None |
| 6/61/F | Malignant lymphoma | Biopsy | 30 Gy WB/14 Fx | MTX, ICE, other* |
| 7/21/M | Medulloblastoma | Partial removal | 32 Gy WB with 22 Gy boost/22 Fx | ICE, CE |
| 8/26/M | Pineal germinoma | Biopsy | 30 Gy WB with 20 Gy boost/20 Fx | CE |
Note.—WB indicates whole brain; Fx, fraction; MTX, methotrexate; ICE, ifosfamide, carboplatin, and etoposide; CE, carboplatin and etoposide; other, other chemotherapy (nimustine, vincristine, procarbazine); other
*
, intrathecal chemotherapy (rituximab).